Abu Dhabi rolls out new programme to detect, treat breast cancer patients

Abu Dhabi has rolled out a new programme that uses cutting-edge, Artificial Intelligence (AI)-based technologies to detect, diagnose and treat breast cancer in the emirate.

The Department of Health – Abu Dhabi (DoH) on Thursday announced the launch of this first Personalised Precision Medicine Programme for oncology in the region, in collaboration with Mubadala Health and its flagship, Cleveland Clinic Abu Dhabi, NYU Abu Dhabi, Mohamed bin Zayed University of Artificial Intelligence and G42 Healthcare.

The new programme will focus its first phase on breast cancer patients across the emirate and treat patients or reduce the risk or recurrence of the disease.

Dr. Jamal Mohammed Al Kaabi, Undersecretary of the Department of Health – Abu Dhabi, said: “By integrating predictive, personalised and precision medicine using genomics we can take the entire process of diagnostics, drug therapy and prevention, and tailor it to the needs of the specific individual.”

Mohamed bin Zayed University of Artificial Intelligence and NYU Abu Dhabi are leading the collaborative research efforts that support the application of genome science in oncology medicine in alignment with DoH’s innovation and research strategy.

The Department of Health - Abu Dhabi developed the regulatory policies and worked with Cleveland Clinic Abu Dhabi to design the programme with core focus on development of clinical testing guidelines and utilising data to create customised treatment plans and counselling for patients.